Biogen Idec’s new multiple sclerosis pill is officially in the hands of patients, and they are footing a hefty bill. The pill, dubbed Tecfidera, is priced at $55,000 per year. Biogen (Nasdsaq: BIIB) has hinted at the possibility of manufacturing Tecfidera locally at its leased Eisai facility. In light of that, I asked Richard Francis, senior vice president of U.S. Commercial Operations at Biogen, to walk me through how Biogen prices its drugs.
